For subgroup analysis for each cancer type, endometrial cancer (HR 3.07, 95% CI 1.62–5.79, p = 0.0006), ovarian cancer (HR 2.37, 95% CI 1.18–4.79, p = 0.02), B-cell lymphoma/leukemia (HR 2.03, 95% CI 1.53–2.69, p < 0.0001), and breast cancer (HR 1.73, 95% CI 1.19–2.54, p = 0.004) showed significant results indicating better prognosis of low ROR1 expression. Here, ROR1 is linked to breast cancer.